Corbus Seeking Way Forward In Systemic Sclerosis After Phase III
Results For Placebo On Par With High-Dose Lenabasum
Executive Summary
The company explained that background immunosuppressant therapy performed better than anticipated based on scientific literature and physicians’ expectations.
You may also be interested in...
Finance Watch: Kronos Bio IPO Raises $250m To Fund Novel Cancer Drugs
Initial public offerings by Norbert Bischofberger’s start-up as well as Spruce Biosciences and Shattuck Labs bring the US total to 64 in 2020. Also, the pipeline of health care SPACs is growing, Everest and Genor went public in Hong Kong, Idorsia leads recent follow-on offerings and Corbus cuts jobs.
Ziritaxestat Phase II Success Gives Galapagos Something To Cheer
It has been a tough couple of months for the Belgian biotech since the FDA surprisingly rebuffed its JAK inhibitor filgotinib but promising data on the oral autotaxin inhibitor ziritaxestat helped soften the blow and drive up Galapagos stock.
Asia Deal Watch: Boost For Esperion's Cholesterol Candidate As Daiichi Brought On Board
Daiichi Sankyo pays $150m upfront to commercialize Esperion's cholesterol drug and combination in Europe, while Gilead enters major deal worth up to $785m with Korea's Yuhan to bolster its NASH portfolio. Samsung taps 3SBio to build its biosimilars business in China.